Level C· Early human research exploring benefitsRetrospective StudyPubMedOpen access

Mesenchymal Stem Cells injection in hip osteoarthritis: preliminary results.

Dall'Oca C., Breda S., Elena N., Valentini R., Samaila EM., Magnan B.

Retrospective Study with a reported sample of 6 on Osteoarthritis, Hip Osteoarthritis, published in Acta Biomed (2019) — summary generated from the PubMed abstract.

Open my reading list
Level C· Early human research exploring benefitsEvidence level of this study

Early human evidence such as case series or small samples is exploring possible benefits.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Retrospective Study
Journal
Acta Biomed (2019)
Country
Italy
Reported sample size
6
Source database
PubMed
PMID
30715002
PMCID
PMC6503401
DOI
10.23750/abm.v90i1-S.8084
Citations
31

Abstract (original English)

Background and aim of the work Osteoarthritis will become even more common in the near future since the average life span is steadily growing. Pain and loss of function are the main complaints reported by patients, inevitably leading towards a worsened daily life performance. New modern techniques have been developed with advanced cell based therapies. Mesenchymal stem cells (MSC) have the inner ability to mature into different types of cells depending on the stimuli they undergo. This technique has already been proven successful in the knee and, with this retrospective study, we would like to assess its feasibility in the hip joint. Methods 6 consecutive patients affected by hip osteoarthritis were treated by intra-articular injection of autologous adipose-derived MSC between June 2017 and June 2018. Our study included only patients with constant hip pain resistant conservative treatment and OA graded 0-2 on the Tonnis grading scale. All 6 patients were evaluated in the preoperative setting and at the 6 months post-operative mark. Results The HHS showed an improvement from the pre-operative baseline mean value of 67.2±3.4 to the 84.6±6.3 post-operative value. Moreover, the WOMAC score dropped from a baseline score of 36.3±4.7 to 19.8±3.4 at 6 months' post-op follow up visit. Conclusions MSC Lipogems is a fairly easy technique. No adverse effects were recorded in our experience

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.
  • • Without an adequate control group, treatment effects cannot be separated from other factors.

Evidence level

Early human evidence such as case series or small samples is exploring possible benefits.

How we grade evidence
AdultFemaleHumansInjections, Intra-ArticularMaleMesenchymal Stem Cell TransplantationMiddle AgedOsteoarthritis, HipRetrospective StudiesTreatment Outcome

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.

Related research